• Shaji K. Kumar, MD - Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

  • Feb 25 2025
  • Durée: 50 min
  • Podcast

Shaji K. Kumar, MD - Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ESB865. CME/NCPD/AAPA/IPCE credit will be available until February 23, 2026.

    Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.

    Disclosure information is available at the beginning of the video presentation.

    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de Shaji K. Kumar, MD - Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.